Literature DB >> 11343827

Amyloid beta protein deposition in patients with frontotemporal lobar degeneration: relationship to age and apolipoprotein E genotype.

D M Mann1, A M McDonagh, S M Pickering-Brown, H Kowa, T Iwatsubo.   

Abstract

Amyloid beta protein (Abeta) deposition was investigated in the frontal cortex of 54 autopsy cases of frontotemporal lobar degeneration (FTLD) using methenamine silver staining, and immunohistochemistry employing the monoclonal end-specific antibodies BC05 and BA27 to visualize deposits containing Abeta(42(43)) and Abeta(40), respectively. Abeta was detected in 14 (26%) patients, nearly always in the form of diffuse Abeta(42(43)) containing plaques though some cored, neuritic plaques with trace amounts of Abeta(40) were occasionally seen. The 14 patients showing Abeta deposits were significantly older at onset of illness than those 40 patients without Abeta. It was only possible to genotype 46/54 cases, 16 of whom bore at least one copy of the Apolipoprotein E (APOE) epsilon4 allele, giving an allele frequency of 20%. Possession of APOE epsilon4 allele was significantly associated with deposition of Abeta such that 10/16 epsilon4 allele bearers had Abeta deposits. Eight of these ten patients showed only mild to moderate amounts of Abeta, but in two patients, one homozygous and one heterozygous for epsilon4 allele, there was extensive neuritic plaque and neurofibrillary tangle formation. In contrast, only few non-epsilon4 allele bearers (4/30) showed minor Abeta deposits. When stratifying for APOE epsilon4 allele, both bearers and non-bearers of epsilon4 allele with Abeta deposits had a significantly later age at onset than their respective groups without Abeta deposits. We conclude that the likelihood of Abeta deposition, as a secondary and coincidental feature unrelated to the primary pathological process, within the brains of individuals with FTLD will be high if patients have a sufficiently late onset of illness or happen to be a bearer of the APOE epsilon4 allele. Indeed 9/14 patients with Abeta deposits studied here had an onset of illness after 55 years of age and bore APOE epsilon4 allele.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11343827     DOI: 10.1016/s0304-3940(01)01785-2

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

1.  Delivery of Polymeric Nanoparticles to Target Vascular Diseases.

Authors:  Edward Agyare; Karunyna Kandimalla
Journal:  J Biomol Res Ther       Date:  2014-01

2.  Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration.

Authors:  Y A L Pijnenburg; S N M Schoonenboom; P D Mehta; S P Mehta; C Mulder; R Veerhuis; M A Blankenstein; P Scheltens
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-19       Impact factor: 10.154

Review 3.  The many faces of tau.

Authors:  Meaghan Morris; Sumihiro Maeda; Keith Vossel; Lennart Mucke
Journal:  Neuron       Date:  2011-05-12       Impact factor: 17.173

4.  CSF biomarkers in frontotemporal lobar degeneration: relations with clinical characteristics, apolipoprotein E genotype, and neuroimaging.

Authors:  Y A L Pijnenburg; S N M Schoonenboom; F Barkhof; D L Knol; C Mulder; G J Van Kamp; J C Van Swieten; P Scheltens
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

5.  [Frontotemporal dementia in association with a family history of dementia and ApoE polymorphism].

Authors:  M Zintl; M Petkov; G Schmitz; G Hajak; H-H Klünemann
Journal:  Nervenarzt       Date:  2010-01       Impact factor: 1.214

6.  Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration.

Authors:  Petra Steinacker; Corinna Hendrich; Anne-Dorte Sperfeld; Sarah Jesse; Stefan Lehnert; Alice Pabst; Christine A F von Arnim; Felix M Mottaghy; Ingo Uttner; Hayrettin Tumani; Albert Ludolph; Markus Otto
Journal:  J Neural Transm (Vienna)       Date:  2009-08-01       Impact factor: 3.575

7.  Pathological assessments for the presence of hexanucleotide repeat expansions in C9ORF72 in Alzheimer's disease.

Authors:  Yvonne S Davidson; Andrew C Robinson; Julie S Snowden; David M A Mann
Journal:  Acta Neuropathol Commun       Date:  2013-08-12       Impact factor: 7.801

8.  Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration.

Authors:  Sang Won Seo; Marie-Pierre Thibodeau; David C Perry; Alice Hua; Manu Sidhu; Isabel Sible; Jose Norberto S Vargas; Stephanie E Gaus; Gil D Rabinovici; Katherine D Rankin; Adam L Boxer; Joel H Kramer; Howard J Rosen; Maria Luisa Gorno-Tempini; Lea T Grinberg; Eric J Huang; Stephen J DeArmond; John Q Trojanowski; Bruce L Miller; William W Seeley
Journal:  Neurology       Date:  2018-02-16       Impact factor: 9.910

9.  Pedigree with frontotemporal lobar degeneration--motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9.

Authors:  Agnes A Luty; John B J Kwok; Elizabeth M Thompson; Peter Blumbergs; William S Brooks; Clement T Loy; Carol Dobson-Stone; Peter K Panegyres; Jane Hecker; Garth A Nicholson; Glenda M Halliday; Peter R Schofield
Journal:  BMC Neurol       Date:  2008-08-29       Impact factor: 2.474

10.  Interaction of transactive response DNA binding protein 43 with nuclear factor κB in mild cognitive impairment with episodic memory deficits.

Authors:  Yasuyuki Ohta; Cyntia Tremblay; Julie A Schneider; David A Bennett; Frederic Calon; Jean-Pierre Julien
Journal:  Acta Neuropathol Commun       Date:  2014-04-01       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.